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ABSTRACT
Background: Evidence suggests that the consumption of anthocy-
anin-rich foods beneficially affects cardiovascular health; however,
the absorption, distribution, metabolism, and elimination (ADME)
of anthocyanin-rich foods are relatively unknown.
Objective: We investigated the ADME of a 13C5-labeled anthocy-
anin in humans.
Design: Eight male participants consumed 500 mg isotopically la-
beled cyanidin-3-glucoside (6,8,10,3#,5#-13C5-C3G). Biological
samples were collected over 48 h, and 13C and 13C-labeled me-
tabolite concentrations were measured by using isotope-ratio
mass spectrometry and liquid chromatography–tandem mass
spectrometry.
Results: The mean 6 SE percentage½AQ1 of 13C recovered in urine,
breath, and feces was 43.9 6 25.9% (range: 15.1–99.3% across
participants). The relative bioavailability was 12.38 6 1.38%
(5.37 6 0.67% excreted in urine and 6.91 6 1.59% in breath).
Maximum rates of 13C elimination were achieved 30 min after in-
gestion (32.53 6 14.24 mg13C/h), whereas 13C-labeled metabolites
peaked (maximum serum concentration: 5.97 6 2.14 mmol/L) at
10.25 6 4.14 h. The half-life for 13C-labeled metabolites ranged
between 12.44 6 4.22 and 51.62 6 22.55 h. 13C elimination was
greatest between 0 and 1 h for urine (90.306 15.28 mg/h), at 6 h for
breath (132.87 6 32.23 mg/h), and between 6 and 24 h for feces
(557.28 6 247.88 mg/h), whereas the highest concentrations of 13C-
labeled metabolites were identified in urine (10.77 6 4.52 mmol/L)
and fecal samples (43.16 6 18.00 mmol/L) collected between 6 and
24 h. Metabolites were identified as degradation products, phenolic,
hippuric, phenylacetic, and phenylpropenoic acids.
Conclusion: Anthocyanins are more bioavailable than previously
perceived, and their metabolites are present in the circulation for
#48 h after ingestion. This trial was registered at clinicaltrials.org½AQ2
as NCT01106729. Am J Clin Nutr 2013;97:1–9.
INTRODUCTION
Interest in dietary anthocyanins continues to increase as evi-
dence of their vascular bioactivity emerges from epidemiologic,
clinical (randomized controlled trials), and in vitro studies (1–5).
However, over the past decade, there has been ongoing specu-
lation regarding the absorption, distribution, metabolism, and
elimination (ADME)4 and mechanisms of action of anthocya-
nins (6–8). Currently available ADME data from human-in-
tervention studies have suggested maximal serum concentrations
of anthocyanins and anthocyanidin phase II conjugates are, on
average, reached by 1.5 h at amounts ½AQ3of w100 nmol/L after
½AQ4doses of #500 mg anthocyanins (6, 9–13). These findings have
led to the supposition that anthocyanins are considerably less
bioavailable than other flavonoid subclasses. Thus, epidemio-
logic observations that suggested that anthocyanin consumption
is associated with reduced cardiovascular disease risk (1, 14)
appear ambiguous because the average consumption of antho-
cyanins in the diet has been reported to be relatively low (12 mg/
d in the United States) (15). Either anthocyanins are extremely
potent and, therefore, active at low serum concentrations (ie, low
nanomolar concentrations) or their dietary occurrence or bio-
availability has been underestimated.
Evidence based on in vitro gastric (16) and microbial fer-
mentation studies (17, 18) suggested that, after ingestion, an-
thocyanins are likely to be broken down (either spontaneously or
enzymatically) into phenolic degradation products, which are
then further metabolized. Similar findings were observed in
a berry-extract human-consumption study, although because the
intervention contained a complex profile of dietary phenolics, the
metabolites could not be traced back conclusively to the an-
thocyanins over other phenolics within the extract (19). Isotope-
tracer studies are required to conclusively establish the extent to
which anthocyanins are metabolized to phenolic acid derivatives
and the relative contribution of these metabolites to the ab-
sorption, distribution, and elimination of ingested anthocyanins.
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The aim of the current study was to trace metabolites derived
from both phenolic rings (Figure 1, A and B rings) of the parent-
anthocyanin structure, to establish a complete profile of their
absorption and elimination kinetics. To our knowledge, this is
the first study to feed a chemically synthesized multistable-
isotope labeled anthocyanin [cyanidin-3-glucoside (C3G)] to
establish bioavailability and identify metabolites in humans.
SUBJECTS AND METHODS
Isotopically labeled anthocyanin tracer
Isotopically labeled C3G that contained three 13C atoms on the
A ring and 2 13C atoms on the B ring [6,8,10,3#,5#-13C5-C3G
(13C5-C3G); Figure 1] was synthesized as previously described
(20)(with an enrichment of 99 atom% atom percent excess at½AQ5
each position and established as 99.8% pure 13C5-C3G by using
HPLC–tandem mass spectrometry (HPLC-MS/MS) and was
accurately weighed and encapsulated (250-mg gelatin capsules)
at the Ipswich Hospital Pharmaceutical Manufacturing unit.
Subjects
A classic single-bolus oral pharmacokinetic study design was
carried out in 8 healthy male participants recruited from the
University of East Anglia and local community of Norwich,
United Kingdom. The healthy participants were chosen to
maintain a homogeneous study population and minimize meta-
bolic variation. Participants were nonsmokers, had BMI (kg/m2)
in the range from 18.5 to 30.5, and were aged 18–45 y, moderate
drinkers, and not taking dietary supplements. The protocol was
explained to participants, and they provided informed consent.
The study was conducted at the Clinical Research and Trials
Unit at the University of East Anglia according to the principles
expressed in the Declaration of Helsinki and was approved by
the local Research Ethics Committee (ref 10/H0306/42) and
registered at clinicaltrials.org as NCT01106729 ½AQ6.
FIGURE 1. Structure and labeling configuration of 6,8,10,3#,5#-13C5-
cyanidin-3-glucoside.
TABLE 1
Rates of elimination and time of peak elimination observed for the 13C
tracer in 8 healthy adult males after consumption of 500 mg 13C5-C3G
1
Sample
Maximum rate
of elimination
Time of maximum rate
of elimination½AQ16
mg/h h
Blood 32.53 6 14.24 0.5
Urine 90.30 6 15.28 0–1
Breath 132.87 6 32.23 6
Feces 557.28 6 247.88 6–24
1Concentration of 13C was½AQ17 quantified by using liquid chromatography–
isotope-ratio mass spectrometry (mean 6 SE; n = 8). C3G, cyanidin-3-
glucoside.
FIGURE 2. Individual concentrations of 13C tracer in whole blood (A)
and urine (B) across participants after the consumption of a 500-mg bolus
dose of 13C5-cyanidin-3-glucoside by healthy male participants over 48 h
and expanded views of first 6 h (insets). Dashed lines represents means 6
SEs (n = 8). For whole blood (A), the dashed line represents the mean (6SE)
for 8 participants (n = 8); however, several data points are obscured by the x-
axis where the 13C content was below detection limits. For urine (B), the
dashed line represents the mean (6SE) number of participants who provided
a sample in a given period of time: t = 0–1 h (n = 3), t = 1–2 h (n = 6), t = 2–3
h (n = 6), t = 3–4 h (n = 6), t = 4–5 h (n = 4), t = 5–6 h (n = 8), t = 6–24 h (n =
8), and t = 24–48 h (n = 8).
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Study design
After fasting overnight, participants provided blood (30 min
and 1, 2, 4, 6, 24, and 48 h), urine (individual voids between 0 and
6 h; total voids between 6 and 24 and 24 and 48 h), breath (30 min
and 1, 2, 4, 6, 24, 48 h), and fecal (all voids between 0 and6, 6 and
24, and 24 and 48 h) samples after the consumption of a 500-mg
(as two 250-mg capsules) single oral bolus dose of 13C5-C3G (see
Figure 1 under “Supplemental data” in the online issue). A
standardized breakfast was provided 30 min postbolus and
a standardized lunch between the 2- and 4-h sample-collection
time points. Standardized breakfasts were also provided on each
of the follow-up days (for 24 and 48 h).
Dietary intake
Participants were asked to avoid anthocyanin-rich foods and
foods that contained a higher natural abundance of 13C (21) over
the 7-d period (washout period) before the administration of the
capsule and during the intervention (a list of foods to avoid was
provided). Completed food diaries during the washout period (3
d), study day, and 4-h follow-up were monitored for compliance.
Macronutrient and micronutrient intakes were calculated with
the WISP software package (version 3; Tinuviel Software), and
polyphenol intake was determined with the Phenol Explorer
V2.0 database (http://www.phenol-explorer.eu) (22).
Biological sample collection
Blood was collected via a cannula for the first 6 h and via
venepuncture at 24 and 48 h into untreated 10-mL evacuated
tubes. For isotope-ratio mass-spectrometry (IRMS) analysis,
whole blood samples were aliquoted½AQ7 into cryovials (Sigma Al-
drich) and frozen immediately in liquid nitrogen, whereas for
the HPLC-MS/MS analysis, blood samples were allowed to clot
for 1 h followed by centrifugation at 3000 3 g for 10 min. The
serum was acidified to pH 2.4 with formic acid by using a pH
meter (Omega) to prevent degradation of anthocyanins (16) and
aliquoted into cryovials for storage. Breath samples were col-
lected simultaneously (with blood samples) by using the Al-
veosampler system (QuinTrony) and stored in 10-mL evacuated
tubes at room temperature for IRMS. Individual and complete
urine voids were collected into Urisafe collection containers
(VWR International) with 100 mg ascorbate added per 500 mL
urine and were acidified manually to pH 2.4 with formic acid.
Individual fecal voids were collected into custom-made stool-
collection kits, weighed, and transferred to ultracold storage
containers (Nalgene). All blood, serum, urine, and feces samples
were stored at 2808C until analysis.
Analytic methods
Chemicals and materials
C3G was obtained from Extrasynthese, whereas phase II
conjugates of phenolic acids [protocatechuic acid (PCA)–3-
glucuronide, PCA-4-glucuronide, vanillic acid-4-glucuronide,
benzoic acid-4-glucuronide, isovanillic acid-3-glucuronide, iso-
vanillic acid-3-sulfate, PCA-4-sulfate, vanillic acid-4-sulfate,
PCA-3-sulfate, and benzoic acid-4-sulfate] were synthesized as
previously described (23). HPLC-MS/MS–grade methanol and
acetonitrile were purchased from Fisher Scientific. Strata-X
solid-phase extraction (SPE) columns (6 mL, 500 mg), a Ki-
netex polyfluorophenol RP-HPLC ½AQ8column (2.6 mm; 100 3 4.6
mm), and SecurityGuard cartridges (polyfluorophenol; 4 3 2.0
mm) were purchased from Phenomenex. Bond Elute C18 (20
mL; 5 g) SPE columns were purchased from Agilent. Discovery
DSC-18 SPE columns (6 mL; 1 g) and Acrodisc 13-mm, 0.45-mm
PTFE syringe filters and all other chemicals were purchased
from Sigma-Aldrich.
IRMS
A total of 0.5 mL whole blood (diluted 1:1 with 0.5 mL 4 M
NaCl) or 1 mL urine samples was transferred to ultrafiltration
cartridges (Amicon Ultra 2; 30,000 MWCO ½AQ9) and centrifuged at
6000 3 g for 20 min. Ultrafiltered blood and urine were sub-
sequently analyzed by using liquid chromatography-IRMS
(IsoPrime) via a direct-injection mode by using previously de-
scribed methods (24, 25). Breath samples were analyzed by
using continuous-flow IRMS (AP 2003; IsoPrime). Aliquots (4 mg)
of each fecal sample were weighed into tin capsules, which
yieldedw400 mg carbon for elemental analysis IRMS (Sercon).
In each IRMS analysis, the CO2 generated was calibrated
against Vienna Pee Dee Belemnite by using calibrated labora-
tory standards as previously described (26).
TABLE 2
Pharmacokinetic characteristics of metabolites in serum over 48 h in 8 healthy adult males after consumption of 500 mg
13C5-C3G
1
Metabolites Cmax tmax AUC0–48 t1/2
mmol/L h mmol $ h/L h
C3G 0.14 6 0.05 1.81 6 0.16 0.31 6 0.13 ND
Degradants 0.72 6 0.23 6.06 6 0.75 9.09 6 3.01 12.44 6 4.22
Phase II conjugates of PCA 2.35 6 0.15 13.44 6 2.46 43.92 6 5.05 29.52 6 8.95
Ferulic acid 0.94 6 0.37 11.29 6 4.23 21.22 6 10.99 51.62 6 22.55
Hippuric acid 1.96 6 1.39 15.69 6 4.07 46.42 6 30.31 21.69 6 4.56
1All values are means 6 SEs. Serum concentrations of metabolites were quantified by using HPLC–tandem mass
spectrometry (n = 8). AUC0–48, AUC (0–48 h); C3G, cyanidin-3-glucoside; Cmax, maximum serum concentration; degra-
dants, sum of protocatechuic acid and phloroglucinaldehyde; ND, analyte identified in too few time points to model
pharmacokinetics (#3); PCA, protocatechuic acid; phase II conjugates of PCA, sum of phase II conjugates of PCA
(including PCA-3-glucuronide, PCA-4-glucuronide, PCA-3-sulfate, PCA-4-sulfate, vanillic acid, isovanillic acid, vanillic
acid-glucuronide, isovanillic acid-glucuronide, vanillic acid-sulfate, isovanillic acid-sulfate, methyl 3,4-dihydroxybenzoate,
and 2-hydroxy-4-methoxybenzoic acid); tmax, time to reach maximum serum concentration; t1/2, elimination half-life.
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HPLC-MS/MS
Serum, urine, and fecal samples were extracted by SPE with
and extraction efficiencies of 84.5 6 15.9% for serum, 84.0 6
9.5% for urine, and 78.8 6 1.3% for feces. Fecal samples were
homogenized, freeze dried, and alcohol extracted (50% metha-
nol in phosphate-buffered saline; pH 2.4) before SPE. Sample
extracts (5 mL) were injected onto a Kinetix PFP column½AQ10
(Phenomonex) and separated with an Agilent 1200 HPLC by
using 0.1% formic acid (vol:vol) in water½AQ11 and 0.1% formic acid
(vol:vol) in acetonitrile (B) at a flow rate of 1.5 mL/min and
gradient that consisted of 1% B at 0 min and was ramped to 30%
B over 32.5 min. Metabolite identification was performed by
using a QTrap 4000 linear ion-trap mass spectrometer (AB-
Sciex) by using multireaction monitoring optimized for the de-
tection of pure standards with a m/z of the parent and daughter
fragments adjusted to +2 or +3 m/z units, which allowed for the
identification of 13C-labeled metabolites. Metabolites were
confirmed on the basis of the retention time and $3 parent-
daughter ion-fragmentation transitions.
Data processing and statistical analysis
IRMS data were collected and expressed as d13C (relative to
Vienna Pee Dee Belemnite) and, where appropriate, converted
to parts per million 13C. Absolute tracer excretion in the breath
was calculated by estimating the CO2 production rate (27) from
the body surface area (28) by using an estimated correction of
physical activity levels (of 1.3) appropriate for sedentary be-
havior (26). Absolute tracer excretion was determined in urine
and feces as the product of the total amount of carbon excreted
calculated from the area ratio of the major ion beam (m/z 44) of
the sample compared with the laboratory standard of known
carbon content and the 13C enrichment of the sample. The
amount of the tracer excreted in each pool was calculated by
summation of the tracer excreted in the study period and ex-
pressed as percentage of the administered dose of 13C. A similar
calculation was undertaken for blood to determine the in-
stantaneous percentage of the dose transiting the serum pool.
HPLC-MS/MS data were collected with Analyst 1.5.1 soft-
ware (ABSciex, California), and the peak-area data for the most
abundant ion-pair transition for each compound was exported to
the Excel 2007 program (Microsoft). The peak area of 13C
metabolites was quantified against the slope of the fitted re-
gression line of pure standards (which had been subtracted for
the baseline ionization signal to account for differences in
background ionization between 13C and 12C compounds). Data
from all individual urine samples were pooled to the nearest 1-h
period during the first 6 h. Fecal concentrations wee expressed
relative to 1 g wet weight. The proportion of 13C-labeled me-
tabolites relative to total 13C was established by calculating the
fractional molar contribution of 13C atoms in the metabolites
and the total 13C concentration (mmol 13C/L)by using the vol-
ume for the urine and fecal water content. Pharmacokinetic
modeling of metabolite concentrations was performed with the
program PKSolver (29) for Excel 2007 (Microsoft) by using
noncompartmental analysis. All values are presented as means
6 SEs (n = 8) unless otherwise stated.
RESULTS
Study participants
Eight male participants, with a mean age of 27.8 6 8.1 y and
BMI of 23.2 6 1.5, completed the study. Anthocyanin con-
sumption (mean6 SD) during the washout period was 3.36 3.5
mg/d (see Table 1 under “Supplemental data” in the online issue
for mean baseline characteristics) and intake was ,0.5 mg on
the study day and follow-up days. The mean basal breath CO2
natural abundance of d13C was 222.85 6 0.68/mil, which ½AQ12in-
dicated a low natural abundance 13C had been achieved across
FIGURE 3. Mean (6SE) concentrations of identified metabolites in
serum (A) and urine (B) after the consumption of a 500-mg bolus dose
of 13C5-C3G by 8 healthy male participants over 48 h and expanded views
of the first 6 h (insets). C3G, cyanidin-3-glucoside; Degradants, sum of
protocatechuic½AQ15 acid and phloroglucinaldehyde; PCA, protocatechuic acid;
phase II conjugates, sum of phase II conjugates of PCA (including PCA-
3-glucuronide, PCA-4-glucuronide, PCA-3-sulfate, PCA-4-sulfate, vanillic
acid, isovanillic acid, vanillic acid-glucuronide, isovanillic acid-
glucuronide, vanillic acid-sulfate, isovanillic acid-sulfate, methyl 3,4-
dihydroxybenzoate, and 2-hydroxy-4-methoxybenzoic acid); Phenylacetic/
Phenylpropenoic, sum of ferulic acid, 3,4-dihydroxyphenylacetic acid, and
4-hydroxyphenylacetic acid.
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participants. Therefore, all participants complied with the study
protocol, and no adverse effects were associated with the single
dose of 13C5-C3G.
Elimination of 13C
The maximal rate of 13C elimination (32.53 6 14.24 mg/h)
was observed at 30 min after ingestion (Table 1), with blood
concentrations of 13C that ranged between 8.91 6 3.99 and
23.47 6 12.05 mg/mL over the first 24 h (Figure 2A), and peak
concentrations were reached at 48 h (33.40 6 13.90 mg/mL).
The sum of all 13C-labeled metabolites reached a total peak
concentration of 5.976 2.14 mmol/L in serum at 10.256 4.14 h
on the basis of pharmacokinetic modeling (Table 2; Figure 3A).
The half-life of 13C-labeled metabolites ranged from 12.44 6
4.22 h for degradation products (PCA and phlor-
oglucinaldehyde) to#51.626 22.55 h for ferulic acid (Table 2).
Maximum elimination rates for 13C (Table 1) in urine (90.30
6 15.28 mg/h) occurred between 0 and 1 h after ingestion
(Figure 2B), in breath occurred at 6 h (132.87 6 32.23 mg/h)
and in feces occurred between 6 and 24 h (557.28 6 247.88 mg/
h). The highest concentration of 13C was observed in urine (1.55
6 0.43 mg/mL) during the 6–24 h (Figure 2B) time period
postingestion, in breath (2341.62 6 1010.22 mg/mL) at 24 h,
and in feces (105.69 6 20.68 mg/g) at 24–48 h (Figure 4A). In
relation to metabolites (sum of all degradants and their metab-
olites), greatest concentrations were shown in 6–24-h urine
samples (10.77 6 4.52 mmol/L; Figure 3B) and 6–24-h fecal
samples (43.16 6 18.00 mmol/L; Figure 4B).
Urine was the primary route of elimination over the first 6 h
(Figure 5A) and represented 66.33 6 13.22% of the total 13C
recovery followed by that in breath (28.94 6 6.89%). Feces
represented the major route of elimination over the 6–24- and
24–48-h time periods (Figure 5A). A similar pattern was ob-
served for metabolites, with highest concentrations of 13C-la-
beled metabolites in urine in the first 6 h (5.57 6 2.56 mmol/L;
Figure 5B), whereas feces was the predominant compartment
thereafter (Figure 5B).
A total of 43.9 6 25.9% of the bolus dose of 13C was re-
covered in urine, breath, and feces, with a wide interindividual
variability (15.1–99.3%) exhibited by participants. Maximum
observed quantities of 13C in blood accounted for 0.18 6 0.11%
of the ingested dose, whereas mean recoveries of 13C were 5.37
6 0.67%, 6.91 6 1.59%, and 32.13 6 6.13% for urine, breath,
and feces, respectively (Figure 5A). Together, these data suggest
a relative bioavailability of $12.38 6 1.38% calculated from
the combined elimination via urine and breath.
Characteristics of 13C-labeled metabolites
A total of 25 13C-labeled compounds that consisted of 13C5-C3G
and 24 labeled metabolites were identified. Metabolites included
phase II conjugates of C3G and cyanidin (cyanidin-glucuronide,
methyl cyanidin-glucuronide, and methyl C3G-glucuronide), de-
gradants (PCA, phloroglucinaldehyde, and phloroglucinaldehyde),
phase II conjugates of PCA (including PCA-3-glucuronide, PCA-4-
glucuronide, PCA-3-sulfate, PCA-4-sulfate, vanillic acid,
isovanillic acid, vanillic acid-glucuronide, isovanillic acid-glucu-
ronide, vanillic acid-sulfate, isovanillic acid-sulfate, methyl 3,4-di-
hydroxybenzoate, 2-hydroxy-4-methoxybenzoic acid, and methyl
vanillate), phenylacetic acids (3,4-dihydroxyphenyl acetic acid and
4-hydroxyphenylacetic acid), phenylpropenoic acids (caffeic acid
and ferulic acid), and hippuric acid.
In serum, C3G reached a peak concentration of 0.14 6 0.05
mmol/L at 1.81 6 0.16 h postconsumption, whereas its degra-
dation products peaked at 0.72 6 0.23 mmol/L (Table 2). The
major metabolites of C3G in serum were phase II conjugates of
PCA, ferulic acid, and hippuric acid, which peaked between 6-
and 24-h collection time points at concentrations between 0.94
6 0.37 and 2.35 6 0.15 mmol/L. The serum concentration AUC
ranged from 0.31 6 0.13 mmol $h/L for C3G to 46.42 6 30.31
mmol $h/L (Table 2) for hippuric acid.
FIGURE 4. Mean (6SE) concentrations of 13C tracer (A) and 13C-labeled metabolites (B) in feces after the consumption of a 500-mg bolus dose of 13C5-
C3G by 8 healthy male participants. Eight participant samples were collected for the 6–24- and 24–48-h time points, whereas 2 participants provided samples
within the first 6 h of sampling. C3G, cyanidin-3-glucoside; Degradants, sum of PCA and phloroglucinaldehyde; PCA, protocatechuic acid; phase II
conjugates; sum of phase II conjugates ofPCA (including PCA-3-glucuronide, PCA-4-glucuronide, PCA-3-sulfate, PCA-4-sulfate, vanillic acid, isovanillic
acid, vanillic acid-glucuronide, isovanillic acid-glucuronide, vanillic acid-sulfate, isovanillic acid-sulfate, methyl 3,4-dihydroxybenzoate, 2-hydroxy-4-
methoxybenzoic acid, and methyl vanillate); Phenylacetic/Phenylpropenoic, sum of ferulic acid, caffeic acid, and 3,4-dihydroxyphenylacetic acid, and 4-
hydroxyphenylacetic acid.
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C3G and its degradants reached a peak in urine at 2 h post-
consumption (Table 3) at 1.78 6 0.18 and 0.48 6 0.10 mmol/L,
respectively (Figure 3B). Also, phase II conjugates of C3G and
cyanidin were identified in the urine at a maximum concentra-
tion of 1.17 6 0.52 mmol/L at 1 h (collectively) and consisted of
cyanidin-glucuronide (m/z 468/454/292), methylated cyanidin-
glucuronide (m/z 482/468/292), and methylated C3G-glucuronide
(m/z 644/482/468/292) on the basis of tandem mass
spectrometry fragmentation patterns and quantified relative to
C3G (because analytic standards were not available). Phase II
conjugates of PCA peaked in the urine at 24 h (5.54 6 0.49
mmol/L), phenylacetic and phenylpropenoic acids at 48 h (1.51
6 0.75 mmol/L), and hippuric acid at 24 h (5.21 6 3.43 mmol/
L). Out of the total 13C recovered in the urine (by using IRMS),
36.72 6 14.39% could be accounted for as 13C-labeled metab-
olites (by using HPLC-MS/MS), with the specific urinary re-
covery of metabolites that ranged from 36.47 6 20.27 ng for
C3G to 1124.89 6 830.70 ng for phase II conjugates of PCA
(Table 4).
Total metabolites present in feces reached a maximal con-
centration at 24 h postconsumption (43.166 18.32 mmol/L) with
phase II conjugates of PCA that reached peak concentrations of
6.94 6 3.59 mmol at 48 h, whereas the majority of fecal me-
tabolites were comprised of phenylpropenoic and phenylacetic
acids (41.69 6 11.55 mmol/L) that peaked at 6–24 h (Figure
4B). The hippuric acid content of feces reached a peak of 0.426
0.17 mmol/L at 24 h (Figure 4B). Out of the total 13C recovered
in feces (by IRMS), 2.01 6 0.01% could be accounted for as
13C-labeled phenolic metabolites (by using HPLC-MS/MS),
with the specific fecal recovery of metabolites that ranged from
0.44 ng for C3G to 56.00 6 34.64 ng for phenylacetic and
propenoic acids (Table 4).
DISCUSSION
C3G was established to have a minimum relative bio-
availability of 12.38 6 1.38% on the basis of the total elimi-
nation of the absorbed 13C dose via urine and breath. In samples
collected, a maximum of 0.18 6 0.11% of the 13C dose could be
recovered from blood, 5.37 6 0.67% of the 13C dose could be
recovered from urine, 6.91 6 1.59% of the 13C dose could
be recovered from breath, and 32.13 6 6.13% of the 13C dose
could be recovered from feces. Previously, anthocyanins have
been reported to have one of the lowest bioavailabilities of all of
the dietary flavonoid subclasses (w0.4%) (7, 30). However, our
data suggested that anthocyanins are as bioavailable as other
flavonoid subclasses, such as flavan-3-ols and flavones, which
have relative bioavailabilities between 2.5% and 18.5% (7, 30).
There was also considerable interindividual variability in the
recovery of the 13C tracer in the current study that ranged from
15.1% to 99.3%, probably as a result of a high variation in
gastric and intestinal transit times, composition, and catabolic
activity of colonic flora and the ability to take up and excrete
catabolites and metabolites (6).
A total of 43.9 6 25.9% of the dose of 13C was recovered in
urine, breath, and feces; however the fate of the remaining in-
gested 13C remains unknown. The recovery of flavonoids similar
in structure to C3G (such as 14C-labeled quercetin) has been
reported to be between 58.5% and 96% (31, 32). Furthermore, of
the total 13C recovered, only 36.726 14.39% and 2.016 0.01%
of the tracer was recovered as 13C-labeled metabolites in the
urine and feces respectively, which suggested that there are
many metabolites still undetected by current HPLC-MS/MS
techniques. On the basis of the instability of anthocyanins and
appearance of a relatively large number of diverse breakdown
products and metabolites, other metabolites might exist at lower
concentrations and, therefore, escape detection.
Serum concentrations of C3G that we observed were similar to
those previously reported (6, 7); however, degradation products
of C3G (PCA and phloroglucinaldehyde) reached collective peak
serum concentrations of 0.726 0.23 mmol/L (Table 2) at 6.066
0.75 h postbolus, which, to our knowledge, has not been
FIGURE 5. Cumulative recovery (6SE) of 13C from whole blood (A) and
13C-labeled metabolites from blood serum (B) after the consumption of
a 500-mg bolus dose of 13C5-cyanidin-3-glucoside by 8 healthy male
participants over 48 h and expanded views of first 6 h (insets).
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previously reported. On the basis of the rapid appearance of
C3G degradation products and their phase II conjugates within
the serum, some degradation likely occurred in the small in-
testine (either preabsorption or postabsorption), which suggested
that anthocyanin C-ring cleavage may not require the action of
colonic microflora as reported for other flavonoids such as
quercetin and catechin (18).
A total of 24 metabolites were identified at concentrations that
ranged from 0.1 to 42.2 mmol/L, whereas a total of 51 putative
metabolites of C3G were initially explored. Seven hydrox-
ybenzoic acids, 10 methoxybenzoic acids, 3 phenylpropenoic
acids, 2 isomers of methylhippuric acid, homovanillic acid,
hydroxybenzylalcohol, benzoic acid-4-sulfate, and hydroxy-
benzaldehydes were either not present or only present in trace
amounts. Although many of the metabolites identified in the
current study have been identified in animal studies (18, 33, 34),
to our knowledge, this is the first study to show this diversity of
metabolites in humans by using a stable-isotope–labeled single-
compound approach.
Estimates of the half-lives of elimination were between 12.44
6 4.22 h and 51.62 6 22.55 h for 13C-labeled metabolites
(Table 2), which suggested a relatively slow urinary clearance of
some metabolites. Long elimination half-lives may be the result
of a combination of hepatic recycling, enterohepatic circulation,
and prolonged colonic production and absorption. Indeed, the
biliary excretion of C3G (35) and other similarly structured
flavonoids (quercetin and catechin) (31, 32, 36, 37) has pre-
viously been reported in animal studies.
The urinary recovery of 13C reached a maximal concentration
in the pooled 6–24-h collections, which represented a peak 13C-
labeled metabolite concentration of 10.77 6 4.52 mmol/L
(Figure 3B). These concentrations were considerably higher
than those previously published (0.02–0.592 mmol/L) (6, 7). In
the breath, peak concentrations of the 13C tracer were detected at
24 h as 13CO2 (Figure 5). To our knowledge, this is the first
human study to report the breath as a route for the clearance of
anthocyanin-derived carbon from the body. The sustained ex-
cretion of the label as 13CO2 over 48 h suggested the prolonged
absorption of low molecular weight fecal metabolites from the
TABLE 3
Peak concentrations of urinary metabolites over 48 h in 8 healthy adult males after consumption of 500 mg 13C5-C3G
1
Metabolites
Maximum
concentration2 Time of maximum concentration
mmol/L h
C3G 1.78 6 0.18 2
Phase II conjugates of C3G and cyanidin 1.17 6 0.52 1
Degradants 0.48 6 0.10 2
Phase II conjugates of PCA 5.54 6 0.49 24
Phenylpropenoic and phenylacetic acids 1.51 6 0.75 48
Hippuric acid 5.21 6 3.43 24
1Urinary concentrations of metabolites quantified by using HPLC–tandem mass spectrometry (n = 8). C3G, cyanidin-
3-glucoside; degradants, sum of protocatechuic acid and phloroglucinaldehyde; PCA, protocatechuic acid; phase II con-
jugates of C3G and cyanidin, sum of cyanidin-glucuronide, methylated cyanidin-glucuronide, and methylated C3G-glucu-
ronide; phase II conjugates of PCA, sum of phase II conjugates of PCA (including PCA-3-glucuronide, PCA-4-glucuronide,
PCA-3-sulfate, PCA-4-sulfate, vanillic acid, isovanillic acid, vanillic acid-glucuronide, isovanillic acid-glucuronide, vanil-
lic acid-sulfate, isovanillic acid-sulfate, methyl 3,4-dihydroxybenzoate, and 2-hydroxy-4-methoxybenzoic acid); phenyl-
propenoic and phenylacetic acids, sum of ferulic acid, 3,4-dihydroxyphenylacetic acid, and 4-hydroxyphenylacetic acid.
2All values are means 6 SEs.
TABLE 4
Recovery of metabolites in biological samples over 48 h in 8 healthy adult males after consumption of 500 mg 13C5-C3G
1
Metabolites Serum2 Urine3 Feces3
ng ng ng
C3G 9.99 6 3.90 36.47 6 20.27 0.444
Degradants 149.88 6 93.20 60.00 6 23.24 7.40 6 1.81
Phase II conjugates of PCA 321.73 6 130.89 1124.89 6 830.70 30.82 6 11.39
Phenylacetic/propenoic acids 153.32 6 60.955 248.59 6 85.28 56.00 6 34.64
Hippuric acid 348.04 6 246.32 309.82 6 261.92 4.26 6 2.29
1All values are means 6 SEs. Metabolite recovery determined by using HPLC–tandem mass spectrometry (n = 8).
C3G, cyanidin-3-glucoside; degradants, sum of protocatechuic acid and phloroglucinaldehyde; PCA, protocatechuic acid;
phase II conjugates of PCA, sum of phase II conjugates of PCA (including PCA-3-glucuronide, PCA-4-glucuronide, PCA-
3-sulfate, PCA-4-sulfate, vanillic acid, isovanillic acid, vanillic acid-glucuronide, isovanillic acid-glucuronide, vanillic
acid-sulfate, isovanillic acid-sulfate, methyl 3,4-dihydroxybenzoate, 2-hydroxy-4-methoxybenzoic acid, and methyl
vanillate).
2Recovery at maximum serum concentration.
3Total recovery.
4C3G was detected in feces of one participant only.
5 Ferulic acid was the only phenylacetic/propenoic acid recovered in serum.
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colon, perhaps derived from labeled-aliphatic compounds or
carboxylic acids or via direct fermentation to 13CO2. Studies in
which 14C-labeled flavonoids were fed to rodents reported be-
tween 8% and 17.5% excretion as 14CO2 (35, 38), in addition to
the presence of 14C-labeled aliphatic intermediates (41). The
greatest proportion of the 13C dose was excreted in feces (32.13
6 6.13%). A previous study reported 44.5% recovery of an oral
bolus dose of 14C-labeled C3G in mice (35,) and fecal recoveries
of other flavonoids have been reported between 1.9% and 30%
(33, 34).
In the current study, there was a 42-fold higher abundance of
13C-labeled metabolites relative to 13C5-C3G at their respective
maximum serum concentration. Previous studies reported a 6-
fold higher proportion of 14C metabolites relative to the parent
anthocyanin in mice fed 14C-labeled C3G (35). Phase II con-
jugates of C3G could only be detected in the urine and reached
peak concentrations of 1.17 6 0.52 mmol/L at 1 h (collectively).
Previous studies in which similarly structured isotope-labeled
flavonoids (quercetin and catechin) were fed have also reported
glucuronide, methyl, or sulfate derivatives of the parent flavo-
noid structure (36–38). Phase II metabolites of PCA were the
primary metabolites identified during the first 6 h in serum and
urine (Figure 3), whereas hippuric, phenylacetic, and phenyl-
propenoic acids and phase II conjugates of PCA were the pre-
dominant metabolites at 24 h in serum. In the 48-h samples,
a mixture of hippuric acid, ferulic acid, and phase II conjugates
of PCA were present (Figure 3).
Although the study was limited to men only, there was a high
variation in ADME observed, which suggested an extremely high
variability in ADME should be expected across mixed-sex
populations as a result of differences in absorption, metabolism,
and, perhaps more importantly, the gut microbiome (18); all of
which should be considered when associations in epidemiologic
studies on the health effects of flavonoid consumption are
interpreted.
A limitation of the current study was the inability to recover all
of 13C label or 13C-labeled metabolites, for which there were
many possible reasons. Primarily, a considerable proportion of
the unrecovered label likely remained in feces .48 h because
concentrations of 13C did not reach their peak by this time
(Figure 5A), which suggested that a longer fecal sampling pe-
riod (perhaps $72 h) would have yielded a greater recovery.
Extraction and quantification methods used were also optimized
for 51 analytes, and therefore, the methods may be less sensitive
in the detection or quantification of other novel metabolites.
Furthermore, extraction efficiencies of the methods used were
75–98% efficient across matrices, which potentially accounted
for #25% of identified metabolites having been quantitatively
underestimated. Although we did not fully recover the 13C dose
(via IRMS) or the relative concentration of 13C-labeled metab-
olites (via HPLC-MS/MS), the current results improved on those
of previous studies in which the recovery of metabolites rarely
exceeded 1% of the dose (7, 10, 11, 19, 39–43). In addition,
previous studies have been unable to trace the kinetics of the A-
ring metabolites as a result of the localization of previously used
isotope labels to the C and B rings of the flavonoid backbone
(36, 38). The synthesizing of a labeled C3G with a different
number of 13C atoms on the A and B rings was a major ad-
vantage in the current study.
In conclusion, the current study indicates that anthocyanins
have a minimum relative bioavailability of 12.3 6 1.3%, and
their metabolites reach a 42-fold higher peak serum concentra-
tion that occurred much later than that of the parent anthocyanin.
Overall, the present study indicated a much higher relative
bioavailability and greater diversity of circulating metabolites
than previously reported. The mechanisms of action and relative
importance of these metabolites on health outcomes should be
the focus of future anthocyanin research.
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